natgillin/translations-raw huggingface dataset:
The method of claims 1-10, wherein the protein carrier is selected from the group consisting of: TT, DT, CRM197, fragment C of TT, protein D of H. influenzae, pneumococcal PhtD, and pneumococcal Pneumolysin. A saccharide-protein carrier conjugate obtainable by the method of claims 1-11. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što svaki od najmanje jednog N. meningitidis saharida je konjugiran s proteinom-nosačem, kojeg se bira iz skupine koju čine TT, DT, CRM197, fragment C od TT, protein D, OMPC i pneumolizin.
A composition according to claim 1, wherein component a) is selected from 1-methionine, 1-cysteine, 1-cystine, taurine, 4-thiazolidinecarboxylic acid, carboximethylcisteine and/or methylsulphonylmethane, or a physiologically acceptable salt thereof. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što komponentu a) se bira između 1-metionina, 1-cistein, 1-cistina, taurina, 4-tiazolidinkarboksilne kiseline, karboksimetilcisteina i/ili metilsulfonilmetana, ili njihovih fiziološki prihvatljivih soli.
Solvent is removed by filtration through the frit under reduced pressure, and the resin is washed by turns five times with DMF and five times with methanol. 
Otapalo se ukloni filtriranjem preko frita uz smanjeni tlak, smola se ispere naizmjenično pet puta s DMF i pet puta s metanolom.
BACKGROUND The present invention generally relates to the production of a beverage or a liquid comestible on the basis of a capsule, which capsule contains ingredients which are able to produce a beverage or liquid comestible when interacting with a liquid, such as for example hot pressurised water, introduced into the volume of the capsule. 
Predmetni izum se općenito odnosi na proizvodnju napitaka ili tekućih prehrambenih proizvoda na temelju čahura, koje čahure sadržavaju sastojke iz kojih se može proizvesti napitak ili tekući prehrambeni proizvod kada se provede interakcija s tekućinom, takvom kao što je na primjer vruća voda pod tlakom, koja se uvede u prostor u čahuri.
Item 3. The use of an AAV vector comprising a therapeutic gene for the manufacture of a medicament for treating a motor neuron disorder in a subject, wherein said AAV vector is administered by peripheral injection to said subject, said administration causing infection of motor neurons or glial cells and expression of the gene in motor neurons or glial cells, wherein said AAV vector is a double-stranded self-complementary AAV vector. 
AAV vektor koji sadrži terapijski gen za uporabu u metodi za liječenje poremećaja motoričkih neurona u subjekta, pri čemu se navedeni AAV vektor daje intraperitonealnim (i.p.), intramuskularnim (i.m.) ili intravenskim (i.v.) injiciranjem, poželjno intravenskim injiciranjem, navedenom subjektu, navedena primjena uzrokuje infekciju motoričkih neurona ili glija stanica 1 ekspresiju gena u motoričkim neuronima ili glija stanicama, pri čemu je navedeni AAV vektor:
said rotor (30) is coupled with a drive shaft (31), 
- < navedeni rotor (30) je spregnut s pogonskim vratilom (31),
The combined extract was washed with water, washed with saturated aqueous sodium bicarbonate solution, dried and evaporated under vacuum to a residue, which was crystallized from hexane (500 ml.) 
Spojeni ekstrakt se ispere s vodom, ispere se sa zasićenim vodenom otopinom natrij-bikarbonata, suši se i ispari u vakuumu do ostatka, koji se kristalizira iz heksana (500 ml.)
A method according to any one of claims 1 to14 wherein the folinic acid is administered intravenously immediately after aflibercept administration. 
Kombinacija za uporabu prema bilo kojem od zahtjeva 1 do 12 naznačena time da se folinska kiselina primjenjuje intravenozno neposredno nakon primjene aflibercepta.
substituted or unsubstituted C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl; 
R je C,-Ca nerazgranati alkil ili C3-Ca razgranati alkil; ili njegova farmaceutski prihvatljiva sol.
The humanized antibody or fragment thereof of claim 11, wherein the amino acid substitution is at an amino acid position selected from the group consisting of 23, 35b, 48, 50, 60, and 62, wherein the amino acid position of each group member is indicated according to the Kabat numbering. 
Humanizirano protutijelo ili njegov fragment sukladno patentnom zahtjevu 6 ili 7, naznačeno time da, modifikacija amino kiseline sadrži aminokiselinsku supstituciju na poziciji amino kiseline odabrano iz skupine koja sadrži 23, 35b, 48, 50, 60, i 62, pri čemu je pozicija amino kiseline svakog člana skupine naznačena sukladno Kabat numeraciji.
mixing the n conjugates prepared in step (1), to give a composition that includes the common carrier in an unconjugated form, wherein the concentration of the unconjugated common carrier is less than 10 µg/ml. 
miješanje n konjugata pripremljenih u koraku (1), tako da daje sastav koji uključuje zajednički nosač u nekonjugiranom obliku, gdje je koncentracija nekonjugiranog zajedničkog nosača manja od 10 ug/ml.
A composition suitable for control of diseases caused by phytopathogens comprising a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I [image] naznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj fludioksonil.
one to three additional therapeutic agents, optionally wherein the one to three one additional therapeutic agents is an anti-HIV agent, optionally wherein the one to three additional therapeutic agents is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, and combinations thereof; or ii) a first additional therapeutic agent selected from the group consisting of: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent selected from the group consisting of emtricitibine and lamivudine. 
Farmaceutski pripravak prema zahtjevu 13 naznačen time da nadalje sadrži i) jedan do tri dodatna terapeutska sredstva, proizvoljno pri čemu je jedno do tri dodatna terapeutska sredstva sredstvo protiv HIV-a, proizvoljno pri čemu je jedno do tri dodatna terapeutska sredstva izabrano iz skupine koju čine inhibitori HIV proteaze, HIV nenukleozidni inhibitori reverzne transkriptaze, HIV nukleozidni ili nukleotidni inhibitori reverzne transkriptaze, i njihove kombinacije; ili ii) prvo dodatno terapeutsko sredstvo izabrano iz skupine koju čine: abakavir sulfat, tenofovir, tenofovir dizoproksil fumarat, tenofovir alafenamid, i tenofovir alafenamid hemifumarat i drugo terapeutsko sredstvo izabrano iz skupine koju čine emtricitibin i lamivudin.
To this end, it further comprises an implantable movement restriction device adapted to be at least partly invaginated by the patient's stomach fundus wall and having an outer surface that includes a biocompatible material, wherein a substantial part of the outer surface of the movement restriction device is adapted to rest against the stomach wall without injuring the latter in a position between the patient's diaphragm and at least a portion of the lower part of the invaginated stomach fundus wall, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, when the movement restriction device is invaginated, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen, the movement restriction device having a size of at least 125 mm3 and a circumference of at least 15 mm. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što uređaj za rastezanje ima prvi međudjelujući element (10"; 110a; 210a; 410b), prilagođen za međudjelovanje s prvim dijelom stijenke želuca, i drugi međudjelujući element (10"; 110b; 2106; 410b), prilagođen za međudjelovanje s drugim dijelom stijenke želuca, blizu, no odvojen od prvog dijela želuca, gdje je uređaj za rukovanje prilagođen za rukovanje prvim i drugim međudjelujućim elementom kako bi ih se razmaknulo jednog od drugog, kada međudjelujući elementi međudjeluju s prvim i drugim dijelom želuca kako bi rastegnuli dio stijenke želuca između prvog i drugog dijela želuca, tako da se postigne privremeni osjećaj sitosti.
Vacuum distillation apparatus for separating gold-silver alloys according to claim 1, characterised in that the apparatus is provided with three hemispherically shaped condensers. 
Aparat za vakuum destilaciju za razdvajanje zlato-srebro legura u skladu sa patentnim zahtjevom 2, naznačen time što aparat je osiguran sa tri hemisferično oblikovana kondenzatora (7).
A packaging method according to claim 1, wherein the filter used in operations (b1.3) and (b3.3) is made of paper. 
Postupak pakiranja u skladu s patentnim zahtjevom 1, naznačen time, da je filter korišten u operacijama (b1.3) i (b3.3) načinjen od papira.
Rudder according to claim 1, wherein a single transverse plate (2,3) connects two auxiliary rudders (13,23) to the main rudder. 
Kormilo u skladu s patentnim zahtjevom 1, pri čemu pojedina poprečna ploča (2, 3) spaja dva pomoćna kormila (13, 23) s glavnim kormilom.
Example 8 Martensitic Transformation by Means of Ultrasound 
Primjer 8 - Martenzitska transformacija pomoću ultrazvuka
Process for producing a dry concentrate with beebread for making a dietetic soft drink IS CHARACTERIZED BY THAT the substances taking part in the production of dry concentrate in precisely measured mass percentages: beebread triturate 0,175 mass% sieved through a sieve with openings 0,75 mm, the beebread triturate containing 10 mass% of lyophilized beebread and 90 mass% of sucrose, chelate iron (20%) 0,425 mass%, vitamin C 0,4 mass% sieved through a sieve with openings 0,75 mm, mixture of natural aroma and color 4 mass% sieved through a sieve with openings of 0,75 mm, powdered fruit acid, especially anhydrous citric acid, 3,75 mass% sieved through a sieve with openings of 1 mm and suchrose 90,25 mass% sieved through a sieve with openings of 1 mm, micronized SiO2 or MgO 1 mass% according to the mentioned order are thrown in the chromium mixer and are mixed until a homogenous mixture is obtained. 
Postupak za proizvodnju suhog koncentrata sa matičnom mliječi za pripravu dijetetskog osvježavajućeg napitka, naznačen time, što se tvari koje sudjeluju u proizvodnji suhog koncentrata u točno izmjerenim masenim postotcima: triturat matične mliječi 0,175 mas % prosijan kroz sito veličine otvora 0,75 mm, triturat matične mliječi sa 10 mas % liofilizirane matične mliječi i 90 mas % saharoze, kelatno željezo (20%) 0,425 mas %, vitamin € 0,4 mas % prosijan kroz sito veličine otvora 0,75 mm, mješavina prirodne arome i boje 4 mas % prosijana kroz sito veličine otvora 0,75 mm, voćna kiselina u prahu, naročito anhidrirana limunska kiselina, 3,75 mas % prosijana kroz sito veličine otvora 1 mm i saharoza 90,25 mas % prosijana kroz sito veličine otvora 1 mm, mikronizirani SiO, ili MgO 1 mas %, prema naprijed navedenom redoslijedu ubace u nehrđajuću miješalicu i miješaju do dobivanja homogene smjese.
is a member selected from the group consisting of: 
R' član odabran iz grupe koja se sastoji od: lu, DO .
Compounds of formula (III) may be prepared by reacting a compound of formula (IV) 
Postupak dobivanja spoja formule (III), naznačen time što se navedeni postupak sastoji u reakciji spoja formule (IV)
In some embodiments, in the second dosage composition, the proton pump inhibitor is one of omeprazole, pantoprazole, lansoprazole, ilaprazole, dexlansoprazole, esomeprazole and rabeprazole, pharmaceutically acceptable salt and solvates thereof or combinations thereof. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time što u pripravku druge doze inhibitor protonske pumpe sadrži omeprazol, pantoprazol, lansoprazol, ilaprazol, dekslansoprazol, esomeprazol ili rabeprazol, farmaceutski prihvatljive soli ili njihove solvate ili kombinacije navedenog.
A recombinant eukaryotic or a prokaryotic cell which produces an antibody which comprises: 
Rekombinantna eukariotska ili prokariotska stanica, naznačena time što proizvodi protutijelo koje sadrži:
The bulking fibre composition comprises 30 to 75, preferably 45 to 65, weight % of polysaccharide, 5 to 45, preferably 10 to 30, weight % of oligosaccharide, the total of the sugar replacement composition being 100 weight %. 
Sastavina vlakana koja povećavaju masu sadržava 30 do 75, po mogućnosti 45 do 65 težinskih % polisaharida 1 5 do 45, po mogućnosti 10 do 30 težinskih % oligosaharida, pri čemu ukupni sadržaj sastavine koja zamjenjuje šećer iznosi 100 težinskih %.
an immunogenically active peptide fragment of the lndoleamine 2,3-dioxygenase (IDO) of SEQ ID NO:1, consisting of up to 25 consecutive amino acids of SEQ ID NO: 1 which comprise the sequence of SEQ ID NO: 6; and 
imunogenski aktivni peptidni fragment indoleamin 2,3-dioksigenaze (IDO) sa SEQ ID NO:1, koji se sastoji od najviše 25 uzastopnih aminokiselina sa SEQ ID NO:1 koje sadrže sekvencu SEQ ID NO:6; i
Also as shown in Figure 11, the members 1104 have a generally rectangular shape. 
Kao što je također prikazano na Slici 11, dijelovi 1104 su općenito pravokutnog oblika.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound mandipropamid. 
(A) spoja formule (I) naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) barem jednog spoja odabranog iz skupine koja se sastoji od (Bl) - strobilurin fungicida.
The process according to claim 1, wherein R3 is selected from the group consisting of methyl, butyl, and phenyl, optionally substituted with methyl. 
Spoj prema zahtjevu 19, naznačen time da je X odabran iz skupine koja sadrži: fenil, metil supstituirani fenil, metil i butil.
Typical examples of pharmaceutically acceptable organic and mineral bases are: mono-, di- and trialkylamines, for instance methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, propylamine, dipropylamine, tripropylamine, ethylenediamine, mono-, di- and trialkanolamines, for instance monoethanolamine, diethanolamine and triethanolamine; guanidine, morpholine, piperidine, pyrrolidine, piperazine, 1-butylpiperidine, 1-ethyl-2-methylpiperidine, N-methylpiperazine, 1,4-dimethylpiperazine, N-benzylphenylethylamine, N-methylglucosamine, tris(hydroxymethyl)aminomethane, ammonia, sodium hydroxide, calcium hydroxide, potassium hydroxide, aluminium hydroxide, iron hydroxide, magnesium hydroxide and zinc hydroxide. 
Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time, da je navedena farmaceutski prihvatljiva organska ili mineralna lužina odabrana iz skupine koju čine metilamin, dimetilamin, trimetilamin, etilamin, dietilamin, trietilamin, = propilamin, - dipropilamin, tripropilamin, etilendiamin, -monoetanolamin, = dietanolamin, trietanolamin, guanidin, morfolin, piperidin, pirolidin, piperazin, 1-butilpiperidin, 1-etil-2-metilpiperidin, N-metil-piperazin, 1,4-dimetilpiperazin, N-benzilfeniletilamin, N-metilglukozamin, tris(hidroksimetil)aminometan, arginin, lizin, amonijak, natrijev hidroksid, kalcijev hidroksid, kalijev hidroksid, aluminijev hidroksid, željezni hidroksid, magnezijev hidroksid i cinkov hidroksid.
The compound of claim 5, which is: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 
A NZ, ' ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer.
q is an integer ranging from 0 to 6; r is an integer ranging from 0 to 5; and t is an integer ranging from 0 to 2. 
q je cijeli broj unutar intervala od 0 do 6; a r je cijeli broj unutar intervala od 0 do 5.
In still another particular embodiment, a method is provided for producing ADAMTS13 in a continuous cell culture, the method comprising (a) culturing non-anchorage dependent cells mammalian cells expressing recombinant ADAMTS13 protein in a continuous cell culture system, where the cell culture system comprises a macroporous microcarrier cell retention device having a cell retention rate of less than 90%, and has a dilution rate (D) between 0.1 and 1.0 d−1 and a cell density of less than 1×107 cell/mL; and (b) recovering the ADAMTS13 from medium removed from the cell culture system. 
(a) kultiviranje stanica sisavaca koje eksprimiraju polipeptid u kontinuiranom sustavu stanične kulture, pri čemu navedeni sustav stanične kulture sadrži uređaj za zadržavanje stanica 1 ima stupanj razrjeđenja (D) od manje od 2 d"' i gustoću stanica od manje od 2 X 10 " stanica/mL; i (b) obnavljanje navedenog polipeptida iz medija uklonjenog iz navedenog sustava stanične kulture; pri čemu su navedene stanice genetički modificirane kako bi eksprimirale sličan disintegrinu i metalopeptidaza s trombospondinom tip 1 motiv 13 (ADAMTS13) protein.
A compound having formula VIIb: 
Tvar koja ima formulu VIIb:
Tightening clamp as claimed in claim 1, wherein said fixed abutment element consists of prongs of a fork (14) projecting from the fastening arm (3). 
Stezaljka za pričvršćivanje prema bilo kojem od prethodnih patentnih zahtjeva naznačena time da se navedeni čvrsti element za podupiranje sastoji od viličastih zubaca (14) koji izlaze iz stežućeg dijela (3).
The wind power installation according to claim 10 wherein the wind power installation is FACTS-capable and has one or more converters for rectifying produced electric energy of the generator and converting to the electric energy into an AC signal for providing to an electric network in adapted relationship to frequency, voltage and phase in the electric network. 
Vjetrogenerator prema zahtjevima 8 ili 9, naznačen time da vjetrogenerator ima FACTS-sposobnost, i/ili jedan ili više konvertora za ispravljanje električne energije koju proizvede generator i njezino ponovno pretvaranje u naizmjeničnu struju za napajanje električne mreže s frekvencijom, naponom i fazom koji su prilagođeni električnoj mreži.
the compound is not reduced by 5a-reductase; 
5a-reduktaza ne reducira spoj;
The pharmaceutical composition for use according to claim 11, wherein the composition comprises lactose and/or modified lactose and/or sucrose and/or glucose and/or mannitol and/or modified mannitol and/or sorbitol and/or fructose and/or cellulose and/or cellulose derivatives and/or starch and/or modified starch and/or dextrin and/or dextrose and/or dextrate and/or maltodextrine and/or salts of calcium and/or salts of magnesium and/or crospovidone and/or copovidones and/or cyclodextrines and/or alginic acid and its salts and/or saccharine and/or its salts, and/or salts of sodium and/or aspartame and/or lactic acid and its salts and/or succinic acid and/or ascorbic acid and/or tartaric acid and/or colloidal silicon dioxide and/or cyclamate and/or benzoic acid and/or benzoic acid salts and/or parabens and/or parabens salts as fillers. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što pripravak sadrži laktozu i/ili modificiranu laktozu i/ili saharozu i/ili glukozu i/ili manitol i/ili modificirani manitol i/ili sorbitol i/ili fruktozu i/ili celulozu i/ili celulozne derivate i/ili škrob i/ili modificirani škrob i/ili dekstrin i/ili dekstrozu i/ili dekstrat i/ili maltodekstrin i/ili kalcijeve soli i/ili magnezijeve soli i/ili umreženi povidon i/ili kopovidone i/ili ciklodekstrine i/ili alginsku kiselinu i njezine soli i/ili saharin i/ili njegove soli, i/ili natrijeve soli i/ili aspartam i/ili mliječnu kiselinu i njezine soli i/ili jantarnu kiselinu i/ili askorbinsku kiselinu i/ili vinsku kiselinu i/ili koloidni silicijev dioksid i/ili ciklamat i/ili benzojevu kiselinu i/ili soli benzojeve kiseline i/ili parabene i/ili soli parabena kao punila.
The process according to claim 1, wherein the ketal or acetal group of the compound of formula (V) is further cleaved in a suitable solvent; 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se ketalnu ili acetalnu skupinu u spoju formule (V) R?
A compound according to Claim 18, wherein the compound is or A compound of Claim 19 and, optionally, an additional therapeutic agent for use in a method of modulating the activity of the GPR11 G-protein-coupled receptor comprising administering to a mammalian patient in need a therapetically effective amount of the above compound. 
Spoj prema bilo kojem od zahtjeva 1 do 12 za uporabu u postupku prevencije, inhibicije ili liječenja napredovanja ili početka bolesti ili poremećaja koji su povezani s aktivnošću GPR protein-vezanog receptora i, po izboru, daljnja uporaba dodatne djelatne tvari gdje:
Example 15. A device according to any of the preceding examples, wherein said tubular member (4) is rotatable within an angle range of 0° to 360° in relation to said flushing unit (5), such as 45° or 90°. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, kod kojega navedeni cijevni element (4) može rotirati unutar kuta u području od 0" do 360" u odnosu na navedenu jedinicu za ispiranje (5), naročito za takav kut kao što je kut od 45* 1li 90"
The spatial logical game according to Claims 1 or 2, characterised in that the enveloping shape is ovoid. 
Igra prostorne logike u skladu s patentnim zahtjevom 1 ili 2, karakterizirana time što je oblik omotača ovalan.
a mobile suctioning device capable of moving along the bottom of the container and suctioning a portion of the water containing settled solids at the bottom of the container, wherein the mobile suctioning device is configured to be activated before an increase in color black component of the bottom of the container exceeds 30% on a CMYK scale and wherein the mobile suctioning device comprises suction points distributed along a bottom of the suctioning device constructed to concentrate suctioning power at the suction points and not resuspend more than 30% of the settled solids in an area of the bottom of the container where the mobile suctioning device moves along; 
pokretanje mobilnog usisnog uređaja radi održavanja povećanja crne komponente boje dna ispod 30% bazirano na CMYK ljestvici, pri čemu se mobilni usisni uređaj pomiče po dnu vodenog tijela i usisava dio vode s dna vodenog tijela koje sadrži nataložene čestice, pri čemu je uređaj sposoban za pomicanje i čišćenje brzinom od 10,000 m2 na 24 sata, i pri čemu pogon mobilnog usisnog uređaja ponovno suspendira ne više od 30% nataloženih čestica s površine na dnu vodenog tijela koja je očišćena pomoću mobilnog usisnog uređaja;
An oligonucleotide equivalent according to claim 4, wherein the nucleotide analogue has a modified base. 
Besmisleni oligonukleotid u skladu s patentnim zahtjevom 4, pri čemu analog nukleotida ima modificiranu bazu ifili modificiranu unutarnukleozidnu vezu.
A composition according to claim 1 for use in a method of treating ophthalmic disorders in a patient comprising topically administering to the patient said composition. The composition according to claim 17 wherein said ophthalmic disorder is selected from the group consisting of: 
Sastav prema zahtjevu 1, naznačen time, da se upotrebljava u postupku liječenja oftalmoloških poremećaja kod pacijenta, gdje postupak obuhvaća topikalnu primjenu navedenog sastava na pacijentu.
The method of Embodiment 3 further comprising a preparation of the compound of formula (6), wherein the method comprises treating a compound of formula (5): or a pharmaceutically acceptable salt thereof, with an aldehyde under suitable conditions to form the compound of formula (6), or a pharmaceutically acceptable salt thereof. 
<I ili njegove farmaceutski prihvatljive soli, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7), ili njegovu farmaceutski prihvatljivu sol.